Monopar Therapeutics (NASDAQ:MNPR) Research Coverage Started at Leerink Partners

Leerink Partners started coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research note released on Monday, Marketbeat.com reports. The brokerage issued an outperform rating and a $115.00 price objective on the stock.

MNPR has been the subject of several other research reports. HC Wainwright set a $105.00 price target on shares of Monopar Therapeutics and gave the stock a “buy” rating in a research report on Monday, September 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, September 24th. BTIG Research lifted their target price on shares of Monopar Therapeutics from $87.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Chardan Capital increased their price target on Monopar Therapeutics from $60.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, September 25th. Finally, Barclays set a $125.00 price target on Monopar Therapeutics and gave the stock an “overweight” rating in a research report on Monday, October 13th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $108.10.

Monopar Therapeutics Stock Down 1.0%

Shares of MNPR opened at $82.58 on Monday. Monopar Therapeutics has a 12-month low of $16.26 and a 12-month high of $105.00. The firm has a market capitalization of $509.52 million, a PE ratio of -24.80 and a beta of 1.35. The stock’s fifty day simple moving average is $76.48 and its 200-day simple moving average is $50.91.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.12. Analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Activity at Monopar Therapeutics

In related news, major shareholder Tactic Pharma Llc sold 550,229 shares of the company’s stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the sale, the insider owned 272,026 shares in the company, valued at $17,303,573.86. This represents a 66.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 20.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MNPR. Vanguard Group Inc. increased its holdings in shares of Monopar Therapeutics by 140.7% in the third quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock worth $17,005,000 after acquiring an additional 121,729 shares in the last quarter. Affinity Asset Advisors LLC acquired a new position in shares of Monopar Therapeutics in the 1st quarter valued at approximately $2,257,000. Geode Capital Management LLC increased its stake in Monopar Therapeutics by 99.7% during the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock worth $3,468,000 after purchasing an additional 48,379 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in Monopar Therapeutics during the 1st quarter worth approximately $673,000. Finally, Jane Street Group LLC acquired a new stake in Monopar Therapeutics during the 1st quarter worth approximately $377,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.